RESUMO
BACKGROUND: Cell-free DNA (cfDNA) concentrations have been described to be inversely correlated with prognosis in cancer. Mutations in HCC-associated driver genes in cfDNA have been reported, but their relation with patient's outcome has not been described. Our aim was to elucidate whether mutations found in cfDNA could be representative from those present in HCC tissue, providing the rationale to use the cfDNA to monitor HCC. METHODS: Tumoral tissue, paired nontumor adjacent tissue and blood samples were collected from 30 HCC patients undergoing curative therapies. Deep sequencing targeting HCC driver genes was performed. RESULTS: Patients with more than 2 ng/µL of cfDNA at diagnosis had higher mortality (mean OS 24.6 vs. 31.87 months, p = 0.01) (AUC = 0.782). Subjects who died during follow-up, had a significantly higher number of mutated genes (p = 0.015) and number of mutations (p = 0.015) on cfDNA. Number of mutated genes (p = 0.001), detected mutations (p = 0.001) in cfDNA and ratio (number of mutations/cfDNA) (p = 0.003) were significantly associated with recurrence. However, patients with a ratio (number of mutations/cfDNA) above 6 (long-rank p = 0.0003) presented a higher risk of recurrence than those with a ratio under 6. Detection of more than four mutations in cfDNA correlated with higher risk of death (long-rank p = 0.042). CONCLUSIONS: In summary, cfDNA and detection of prevalent HCC mutations could have prognostic implications in early-stage HCC patients.
RESUMO
No therapies have been proven to increase survival after a hepatic encephalopathy (HE) episode. We hypothesize that two doses of albumin could improve 90-day survival rates after a HE episode. METHODS: (1) A randomized double-blind, placebo-controlled trial (BETA) was conducted in 12 hospitals. The effect of albumin (1.5 g/kg at baseline and 1 g/kg on day 3) on 90-day survival rates after a HE episode grade II or higher was evaluated. (2) A meta-analysis of individual patient's data for survival including two clinical trials (BETA and ALFAE) was performed. RESULTS: In total, 82 patients were included. Albumin failed to increase the 90-day transplant-free survival (91.9% vs. 80.5%, p = 0.3). A competing risk analysis was performed, observing a 90-day cumulative incidence of death of 9% in the albumin group vs. 20% in the placebo (p = 0.1). The meta-analysis showed a benefit in the albumin group, with a lower rate of clinical events (death or liver transplant) than patients in the placebo (HR, 0.44; 95% CI, 0.21-0.82), when analyzed by a competing risk analysis (90-days mortality rate of 11% in the albumin group vs. 30% in the placebo, p = 0.02). CONCLUSIONS: Repeated doses of albumin might be beneficial for patient's survival as an add-on therapy after an HE episode, but an adequately powered trial is needed.
RESUMO
BACKGROUND & AIMS: Patients with decompensated cirrhosis on the waiting list for liver transplantation (LT) commonly develop complications that may preclude them from reaching LT. Circulatory dysfunction leading to effective arterial hypovolemia and activation of vasoconstrictor systems is a key factor in the pathophysiology of complications of cirrhosis. The aim of this study was to investigate whether treatment with midodrine, an alpha-adrenergic vasoconstrictor, together with intravenous albumin improves circulatory dysfunction and prevents complications of cirrhosis in patients awaiting LT. METHODS: A multicenter, randomized, double-blind, placebo-controlled trial (NCT00839358) was conducted, including 196 consecutive patients with cirrhosis and ascites awaiting LT. Patients were randomly assigned to receive midodrine (15-30â¯mg/day) and albumin (40â¯g/15â¯days) or matching placebos for one year, until LT or drop-off from inclusion on the waiting list. The primary endpoint was incidence of any complication (renal failure, hyponatremia, infections, hepatic encephalopathy or gastrointestinal bleeding). Secondary endpoints were mortality, activity of endogenous vasoconstrictor systems and plasma cytokine levels. RESULTS: There were no significant differences between both groups in the probability of developing complications of cirrhosis during follow-up (pâ¯=â¯0.402) or one-year mortality (pâ¯=â¯0.527). Treatment with midodrine and albumin was associated with a slight but significant decrease in plasma renin activity and aldosterone compared to placebo (renin -4.3 vs. 0.1â¯ng/ml.h, pâ¯<â¯0.001; aldosterone -38 vs. 6â¯ng/dl, pâ¯=â¯0.02, at week 48 vs. baseline). Plasma norepinephrine only decreased slightly at week 4. Neither arterial pressure nor plasma cytokine levels changed significantly. CONCLUSIONS: In patients with cirrhosis awaiting LT, treatment with midodrine and albumin, at the doses used in this study, slightly suppressed the activity of vasoconstrictor systems, but did not prevent complications of cirrhosis or improve survival. LAY SUMMARY: Patients with cirrhosis who are on the liver transplant waiting list often develop complications which prevent them from receiving a transplant. Circulatory dysfunction is a key factor behind a number of complications. This study was aimed at investigating whether treating patients with midodrine (a vasoconstrictor) and albumin would improve circulatory dysfunction and prevent complications. This combined treatment, at least at the doses administered in this study, did not prevent the complications of cirrhosis or improve the survival of these patients.
Assuntos
Albuminas/uso terapêutico , Cirrose Hepática/complicações , Cirrose Hepática/tratamento farmacológico , Transplante de Fígado , Midodrina/uso terapêutico , Choque/prevenção & controle , Vasoconstritores/uso terapêutico , Adulto , Idoso , Albuminas/administração & dosagem , Aldosterona/sangue , Ascite , Método Duplo-Cego , Feminino , Seguimentos , Humanos , Hiponatremia/etiologia , Hiponatremia/prevenção & controle , Estimativa de Kaplan-Meier , Cirrose Hepática/mortalidade , Masculino , Pessoa de Meia-Idade , Midodrina/administração & dosagem , Norepinefrina/sangue , Insuficiência Renal/etiologia , Insuficiência Renal/prevenção & controle , Renina/sangue , Resultado do Tratamento , Vasoconstritores/administração & dosagemRESUMO
BACKGROUND: Ornithine phenylacetate (OP) has been proven effective in lowering ammonia plasma levels in animals, and to be well tolerated in cirrhotic patients. A trial to assess OP efficacy in lowering plasma ammonia levels versus placebo in cirrhotic patients after an upper gastrointestinal bleeding was performed. The primary outcome was a decrease in venous plasma ammonia at 24 hours. METHODS: A total of 38 consecutive cirrhotic patients were enrolled within 24 hours of an upper gastrointestinal bleed. Patients were randomized (1:1) to receive OP (10 g/day) or glucosaline for 5 days. RESULTS: The primary outcome was not achieved. A progressive decrease in ammonia was observed in both groups, being slightly greater in the OP group, with significant differences only at 120 hours. The subanalysis according to Child-Pugh score showed a statistically significant ammonia decrease in Child-Pugh C-treated patients at 36 hours, as well as in the time-normalized area under the curve (TN-AUC) 0-120 hours in the OP group [40.16 µmol/l (37.7-42.6); median (interquartile range) (IQR)] versus placebo group [65.5 µmol/l (54-126);p = 0.036]. A decrease in plasma glutamine levels was observed in the treated group compared with the placebo group, and was associated with the appearance of phenylacetylglutamine in urine. Adverse-event frequency was similar in both groups. No differences in hepatic encephalopathy incidence were observed. CONCLUSIONS: OP failed to significantly decrease plasma ammonia at the given doses (10 g/day). Higher doses of OP might be required in Child-Pugh A and B patients. OP appeared well tolerated.
RESUMO
In this paper, the Special Interest Group on Attention Deficit Hyperactivity Disorder (GEITDAH, from its name in Spanish) presents a consensus reached by experts from all over Spain on conduct disorders in children and adolescents. Following the initial work by the team at the Pedopsychiatry Unit at the Quiron-Teknon Hospital in Barcelona, agreements have been reached on a number of basic aspects that could be the starting point for future consensuses. A top priority aim of the work was also to update the criteria in the Diagnostic and statistical manual of mental disorders, fifth edition, for conduct disorders in children and adolescents, together with their comorbidity with attention deficit hyperactivity disorder.
TITLE: Consenso del GEITDAH sobre los trastornos de conducta en niños y adolescentes.El Grupo de Especial Interes en el Trastorno por Deficit de Atencion/Hiperactividad (GEITDAH) presenta en este articulo un consenso de expertos de toda España sobre los trastornos de conducta en niños y adolescentes. A partir del trabajo inicial del equipo de la Unidad de Paidopsiquiatria del Hospital Quiron-Teknon de Barcelona, se han consensuado aspectos basicos que podrian ser el punto de partida para futuros consensos. Ha sido tambien objetivo prioritario del trabajo actualizar en los trastornos de conducta en niños y adolescentes los criterios del Manual diagnostico y estadistico de los trastornos mentales, quinta edicion, y su comorbilidad con el trastorno por deficit de atencion/hiperactividad.
Assuntos
Transtorno da Conduta , Adolescente , Comportamento do Adolescente , Agressão , Transtorno da Personalidade Antissocial/diagnóstico , Transtorno da Personalidade Antissocial/epidemiologia , Transtorno do Deficit de Atenção com Hiperatividade/epidemiologia , Transtornos de Deficit da Atenção e do Comportamento Disruptivo/diagnóstico , Transtornos de Deficit da Atenção e do Comportamento Disruptivo/epidemiologia , Autoritarismo , Criança , Comportamento Infantil , Transtornos do Comportamento Infantil/diagnóstico , Pré-Escolar , Terapia Combinada , Comorbidade , Transtorno da Conduta/diagnóstico , Transtorno da Conduta/epidemiologia , Transtorno da Conduta/etiologia , Transtorno da Conduta/psicologia , Transtorno da Conduta/terapia , Crime , Diagnóstico Diferencial , Manual Diagnóstico e Estatístico de Transtornos Mentais , Função Executiva , Humanos , Lactente , Relações Pais-Filho , Poder Familiar , Escalas de Graduação Psiquiátrica , Psicoterapia/métodos , Psicotrópicos/uso terapêutico , Ensino/métodos , ViolênciaRESUMO
BACKGROUND & AIMS: Episodic hepatic encephalopathy is frequently precipitated by factors that induce circulatory dysfunction, cause oxidative stress-mediated damage or enhance astrocyte swelling. The administration of albumin could modify these factors and improve the outcome of hepatic encephalopathy. The aim of this study is to assess the efficacy of albumin in a multicenter, prospective, double-blind, controlled trial (ClinicalTrials.gov number, NCT00886925). METHODS: Cirrhotic patients with an acute episode of hepatic encephalopathy (grade II-IV) were randomized to receive albumin (1.5g/kg on day 1 and 1.0g/kg on day 3) or isotonic saline, in addition to the usual treatment (laxatives, rifaximin 1200mg per day). The primary end point was the proportion of patients in which encephalopathy was resolved on day 4. The secondary end points included survival, length of hospital stay, and biochemical parameters. RESULTS: Fifty-six patients were randomly assigned to albumin (n=26) or saline (n=30) stratified by the severity of HE. Both groups were comparable regarding to demographic data, liver function, and precipitating factors. The percentage of patients without hepatic encephalopathy at day 4 did not differ between both groups (albumin: 57.7% vs. saline: 53.3%; p>0.05). However, significant differences in survival were found at day 90 (albumin: 69.2% vs. saline: 40.0%; p=0.02). CONCLUSIONS: Albumin does not improve the resolution of hepatic encephalopathy during hospitalization. However, differences in survival after hospitalization suggest that the development of encephalopathy may identify a subgroup of patients with advanced cirrhosis that may benefit from the administration of albumin.
Assuntos
Albuminas/administração & dosagem , Encefalopatia Hepática/tratamento farmacológico , Cirrose Hepática/tratamento farmacológico , Idoso , Método Duplo-Cego , Feminino , Encefalopatia Hepática/mortalidade , Humanos , Injeções Intravenosas , Cirrose Hepática/mortalidade , Masculino , Pessoa de Meia-Idade , Estudos ProspectivosRESUMO
AIMS: Confirm in patients with cirrhosis and gastrointestinal bleeding the safety of ornithine phenylacetate (OP) and assess the pharmacokinetic profile of OP and its effects on plasma ammonia. BACKGROUND: OP is a drug that has shown experimentally to decrease hyperammonemia and improve hepatic encephalopathy. OP is safe in healthy subjects and in stable patients with cirrhosis, but there are no data in decompensated cirrhosis. METHODS: We performed a study to assess safety and tolerance of OP in cirrhotic patients after an episode of upper gastrointestinal bleeding.Ten patients were included within 24 hours of an upper gastrointestinal bleeding. OP was administered as a continuous infusion up to a maximum of 10 g/24 h (0.42 g/h) for 5 days. The infusion was started at 33% of the target dose and increased at 12-hour intervals achieving target dose at 24 hours. Ammonia was also assessed in control group of 10 patients. RESULTS: No severe adverse events were observed. Mild adverse events were reported in 4 patients. Plasma ammonia (baseline: 80±43 µmol/L) showed a progressive drop between baseline and 36 hours (42±15 µmol/L), 72 hours (44±15 µmol/L), 96 hours (40±24 µmol/L), and 120 hours (33±14 µmol/L). Plasma ammonia at 24 hours was significantly higher in the control group. Plasma glutamine showed a significant decrease (-37% at day 5) and its excretion in urine as phenylacetylglutamine, a progressive rise (52±35 mmol at day 5). CONCLUSIONS: OP is a safe and well-tolerated drug in decompensated cirrhotics that may decrease plasma ammonia by inducing its appearance as phenylacetylglutamine in urine.
Assuntos
Amônia/sangue , Hemorragia Gastrointestinal/etiologia , Cirrose Hepática/fisiopatologia , Ornitina/análogos & derivados , Idoso , Estudos de Coortes , Relação Dose-Resposta a Droga , Feminino , Seguimentos , Glutamina/análogos & derivados , Glutamina/sangue , Glutamina/urina , Humanos , Infusões Intravenosas , Cirrose Hepática/complicações , Masculino , Pessoa de Meia-Idade , Ornitina/administração & dosagem , Ornitina/efeitos adversos , Ornitina/farmacocinética , Fatores de TempoRESUMO
Brain magnetic resonance (MR) study has shown metabolic abnormalities and changes in water distribution of the brain tissue that may relate to the pathogenesis of hepatic encephalopathy (HE). We designed a study to investigate the disturbances in brain water and metabolites during episodic HE using a 3-T MR scanner. Cirrhotic patients with different grades of HE underwent MR during hospitalization (n=18). The MR was repeated at 6 weeks' follow-up (n=14). The results were compared with those of a group of healthy volunteers (n=8). During episodic HE, brain diffusion-weighted imaging showed a high apparent diffusion coefficient (ADC) (12% to 14%) that decreased during follow-up (-1% to -4%). These disturbances were accompanied by high glutamine (581%), low choline (-31%), and low myo-inositol (-86%) peaks on MR spectroscopy. In overt HE, patients showed high glutamine that decreased during follow-up (-22%). In addition, these patients exhibited a rise in plasma S100 beta and enlargement of brain white-matter lesions. In conclusion, several disturbances detected by MR support the presence of impaired brain water homeostasis during episodic HE. Although astrocytes have a major role in this condition, brain edema during episodic HE may be extracellular and does not appear to be directly responsible for the development of neurologic manifestations.
Assuntos
Encéfalo/metabolismo , Colina/metabolismo , Ácido Glutâmico/metabolismo , Encefalopatia Hepática/metabolismo , Espectroscopia de Ressonância Magnética , Água/metabolismo , Idoso , Encéfalo/patologia , Química Encefálica , Edema Encefálico/metabolismo , Edema Encefálico/patologia , Feminino , Seguimentos , Encefalopatia Hepática/patologia , Homeostase , Humanos , Cirrose Hepática/metabolismo , Cirrose Hepática/patologia , Masculino , Pessoa de Meia-Idade , Fatores de Crescimento Neural/sangue , Estudos Prospectivos , Subunidade beta da Proteína Ligante de Cálcio S100 , Proteínas S100/sangueRESUMO
INTRODUCTION: Falls are frequent in patients with cirrhosis and cognitive dysfunction and can deteriorate health-related quality of life (HRQoL). OBJECTIVE: To evaluate the relationship between previous falls and HRQoL in patients with cirrhosis. METHODS: We measured HRQoL in 118 outpatients with cirrhosis using the Medical Outcomes Study Short Form (SF-36) questionnaire, grouping items into the Physical Component Score (PCS) and the Mental Component Score (MCS). The incidence of accidental falls in the 12 months before the study was assessed using a specific questionnaire. The Psychometric Hepatic Encephalopathy Score (PHES) was administered to assess cognitive dysfunction. We considered cognitive dysfunction if PHES was less than -4. HRQoL was compared between patients with falls and patients without falls. RESULTS: HRQoL was lower in patients with previous falls than in patients without falls (P<0.05 in all domains of SF-36). In the multivariate analysis, the only independent factors that affected the HRQoL in the PCS were (B coefficient, 95% confidence interval) cognitive dysfunction (6.5, 3.2-9.7, P<0.001), previous variceal bleeding (3.9, 0.4-7.3, P=0.02), anemia (3.2, 0.07-6.4, P=0.049), and hyponatremia (9.3, 1.07-17.5, P<0.02). Multivariate analysis for MCS showed the independent factors for worse HRQoL were female sex (12.2, 6.9-17.5, P<0.001) and previous falls (10.3, 4.0-16.5, P=0.001). CONCLUSION: Falls and cognitive dysfunction are independent factors associated with impaired HRQoL in patients with cirrhosis. Strategies addressed to improve HRQoL in these patients should consider the treatment of cognitive dysfunction and prevention of falls.
Assuntos
Acidentes por Quedas , Transtornos Cognitivos/etiologia , Cognição , Cirrose Hepática/complicações , Qualidade de Vida , Acidentes por Quedas/estatística & dados numéricos , Idoso , Anemia/etiologia , Anemia/psicologia , Transtornos Cognitivos/diagnóstico , Transtornos Cognitivos/psicologia , Varizes Esofágicas e Gástricas/etiologia , Varizes Esofágicas e Gástricas/psicologia , Feminino , Hemorragia Gastrointestinal/etiologia , Hemorragia Gastrointestinal/psicologia , Humanos , Hiponatremia/etiologia , Hiponatremia/psicologia , Modelos Lineares , Cirrose Hepática/diagnóstico , Cirrose Hepática/fisiopatologia , Cirrose Hepática/psicologia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Testes Neuropsicológicos , Psicometria , Fatores de Risco , Fatores Sexuais , Espanha , Inquéritos e QuestionáriosRESUMO
UNLABELLED: Falls are frequent among patients with debilitating disorders and can have a serious effect on health status. Mild cognitive disturbances associated with cirrhosis may increase the risk for falls. Identifying subjects at risk may allow the implementation of preventive measures. Our aim was to assess the predictive value of the Psychometric Hepatic Encephalopathy Score (PHES) in identifying patients likely to sustain falls. One hundred and twenty-two outpatients with cirrhosis were assessed using the PHES and were followed at specified intervals. One third of them exhibited cognitive dysfunction (CD) according to the PHES (<-4). Seventeen of the forty-two patients (40.4%) with CD had at least one fall during follow-up. In comparison, only 5 of 80 (6.2%) without CD had falls (P < 0.001). Fractures occurred in 4 patients (9.5%) with CD, but in no patients without CD (P = 0.01). Patients with CD needed more healthcare (23.8% versus 2.5%; P < 0.001), more emergency room care (14.2% versus 2.5%; P = 0.02), and more hospitalization (9.5% versus 0%; P = 0.01) as a result of falls than patients without CD. Patients taking psychoactive treatment (n = 21) had a higher frequency of falls, and this was related to an abnormal PHES. In patients without psychoactive treatment (n = 101), the incidence of falls was 32.4% in patients with CD versus 7.5% in those without CD (P = 0.003). In the multivariate analysis, CD was the only independent predictive factor of falls (odds ratio, 10.2; 95% confidence interval, 3.4-30.4; P < 0.001). The 1-year probability of falling was 52.3% in patients with CD and 6.5% in those without (P < 0.001). CONCLUSION: An abnormal PHES identifies patients with cirrhosis who are at risk for falls. This psychometric test may be useful to promote awareness of falls and identify patients who may benefit from preventive strategies.
Assuntos
Acidentes por Quedas , Transtornos Cognitivos/complicações , Cirrose Hepática/complicações , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Estudos Prospectivos , PsicometriaRESUMO
OBJECTIVES: Minimal hepatic encephalopathy (MHE) reduces quality of life and impacts daily functioning. It is known to impair fitness to drive, but deficits in attention and reaction may also be associated with falls. Falls may have important consequences in patients with cirrhosis due to coagulopathy, osteoporosis, and operative risk. However, the relationship between MHE and falls has not yet been evaluated. The objective of this study is to retrospectively investigate whether MHE is associated with falls in patients with cirrhosis. METHODS: We included 130 cirrhotic outpatients and 43 controls. MHE was diagnosed according to the results of the psychometric hepatic encephalopathy score (PHES). We recorded the reported incidence and number of falls in the 12 months before the study, the severity of injuries, and the need for healthcare services. RESULTS: Forty-five (34.6%) patients with cirrhosis exhibited MHE. The proportion of patients with MHE that reported falls (40%) was higher than those without MHE (12.9%, P<0.001), which was similar to controls (11.6%). In patients with MHE, there was a higher need for primary healthcare services (8.8 vs. 0%, P=0.004) and hospitalization (6.6 vs. 2.3%, P=0.34) due to falls than in patients without MHE. Patients on psychoactive drugs (n=21) showed a stronger association between MHE and falls: 6/8 (75%) patients with MHE presented falls vs. 2/13 (15.3%) patients without MHE (P=0.01). In patients not receiving psychoactive drugs (n=109), the incidence of falls was 12/37 (32.4%) in patients with MHE vs. 9/72 (12.5%) in those without MHE (P=0.01). Multivariate analysis showed that MHE (odds ratio (OR): 2.91, 95% confidence interval (CI): 1.13-7.48, P=0.02), previous encephalopathy (OR: 2.87, 95% CI: 1.10-7.50, P=0.03), and antidepressant therapy (OR: 3.91, 95% CI: 0.96-15.9, P=0.05) were independent factors associated to previous falls. CONCLUSIONS: Falls are more frequent in cirrhotic patients with MHE, particularly in those on treatment with psychoactive drugs, and are a significant cause for healthcare and hospitalization requirements.
Assuntos
Acidentes por Quedas/estatística & dados numéricos , Condução de Veículo , Encefalopatia Hepática/complicações , Idoso , Estudos de Casos e Controles , Feminino , Encefalopatia Hepática/diagnóstico , Encefalopatia Hepática/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Razão de Chances , Psicometria , Estudos Retrospectivos , Índice de Gravidade de Doença , Espanha/epidemiologiaRESUMO
Objetivos: determinar a prevalência de imunoglobulina IgG para o vírus da rubéolaem gestantes acompanhadas no Hospital São Lucas da PUCRS, Porto Alegre, Brasil. Métodos: foi realizado um estudo transversal no período de abril a junho de 2004. Foram selecionadas 577 pacientes do ambulatório de pré-natal de baixo risco e do centro obstétrico. Os anticorpos IgG para rubéola foram pesquisados, no sangue das gestantes, por uma técnica de imunoensaio disponível comercialmente. Resultados: a prevalência dos anticorpos para rubéola nas 577 pacientes estudadas foi de 95% (IC95%:93%-97%). Conclusões: este estudo permite conhecer a prevalência da imunidade contra o vírus da rubéola em gestantes, ajudando a lidar com um problema brasileiro de saúde pública subestimado, que é a síndrome da rubéola congênita. Novas pesquisas são necessárias em outras áreas do país, pois a prevalência de imunidade pode variar de acordo com a regiões estudadas e nortear medidas de saúde pública que previnam surtos de rubéola.
Assuntos
Gravidez , Complicações Infecciosas na Gravidez , Cuidado Pré-Natal , Rubéola (Sarampo Alemão)/epidemiologia , Síndrome da Rubéola Congênita , Vírus da Rubéola/imunologiaRESUMO
La contaminacion de los cultivos celulares por Mollicutes es un hecho frecuente en los laboratorios, reportándose hasta un 80% de cultivos contaminados, lo que resulta en ensayos experimentales poco confiables y en productos biológicos poco seguros. Los objetivos del presente estudio fueron: estimar la frecuencia de micoplasmas como contaminantes de cultivos celulares y analizar la eficiencia de un ensayo de PCR que emplea como ADN blanco al gen 16S rARN de los Mollicutes. Se estudiaron 39 cultivos celulares primarios, recibidos para análisis de contaminación, entre julio y diciembre de 2005. Se detectaron micoplasmas en 18/39 (46,2%) cultivos de lineas celulares, mientras que no se detectaron micoplasmas en los cultivos celulares primarios. El análisis mediante Hpall del espacio intergénico 16S- 23S rARN de 6 cultivos positivos determinó dos patrones de restrición. La secuenciación del ADN de dos amplicones identifico a Mycoplasma hyorhinis y a Mycoplasma salivarium como micoplasmas contaminantes. La sensibilidad analítica de la PCR, determinada a partir de diluciones de un cultivo de Mycoplasma hominis fue 0,01 u.c.c./mL (unidades cambiadoras de color por mL), mientras que su especificidad analitica fue 100%. Los resultados de este estudio confirman la importancia de los micoplasmas como contaminantes de cultivos celulares y sugieren que la PCR dirigida al gen 16S rARN es un procedimiento útil para el diagnótico de estos microorganismos.
Assuntos
Poluentes Biológicos , Técnicas de Cultura de Células , Meios de Cultura , Tenericutes , Contaminação BiológicaRESUMO
BACKGROUND AND OBJECTIVE: Comparison of safety and effectiveness of the intramuscular (IM) (deltoid) vs subcutaneous (s.c.) administration of the flu vaccine (FV) in patients on oral anticoagulation therapy. PATIENTS AND METHOD: It was a phase IV, simple blind, 2-parallel groups, randomized trial developed in an urban primary care setting. We included patients taking oral anticoagulation therapy without FV contraindications. The IM administration of the FV in the experimental group was compared with a SC administration in the control group. RESULTS: 59 patients were included. The two groups were comparable at the beginning of the study. INR was not modified following s.c. (p = 0.38) or i.m. (p = 0.49) administration. No systemic side effects were observed. More cutaneous lesions were observed in the S.C. group (71.4%) when compared with the i.m. group (25.8%; p < 0.0001). For the remaining variables, we observed a tendency towards more reported pain in the SC group (35.7 vs 22.6%) and a larger brachial diameter (42 vs 29%) without significant differences. 3.2% of patients in the i.m. group and 7.1% in the s.c. group developed influenza symptoms without significant differences. CONCLUSIONS: Even though the results must be interpreted with caution, currently there appears to be no apparent contraindication for the i.m. administration of the FV. When it is administered subcutaneously, it tends to cause more side effects.
Assuntos
Anticoagulantes/administração & dosagem , Vacinas contra Influenza/administração & dosagem , Administração Oral , Interações Medicamentosas , Feminino , Humanos , Injeções Intramusculares , Injeções Subcutâneas , Masculino , Pessoa de Meia-Idade , Método Simples-CegoRESUMO
Os autores fazem uma revisão bibliográfica sobre as causas mais comuns do corrimento vaginal, com ênfase nas três principais etiologias vivenciadas na prática médica, objetivando a abordagem de aspectos como patogenia, manifestações clínicas, diagnóstico e tratamento
Assuntos
Adolescente , Adulto , Pessoa de Meia-Idade , Feminino , Humanos , Vaginite/diagnóstico , Vaginite/etiologia , Vaginite/fisiopatologia , Vaginite/patologia , Vaginite/terapia , Candidíase Vulvovaginal , Leucorreia , Tricomoníase , Doenças VaginaisRESUMO
A ruptura prematura de membranas ovulares (ruprema) acomete, aproximadamente, 8 por cento das gestações. Associa-se a um elevado índice de complicações materno-fetais, especialmente as infecciosas, requerendo diagnóstico preciso, assim como adequada terapêutica. Os autores fazem uma revisão sobre ruprema, abordando os principais aspectos a este tema relacionados
Assuntos
Gravidez , Feminino , Humanos , Ruptura Prematura de Membranas Fetais/complicações , Ruptura Prematura de Membranas Fetais/diagnóstico , Ruptura Prematura de Membranas Fetais/fisiopatologia , Complicações Infecciosas na Gravidez , Trabalho de Parto Prematuro/complicaçõesRESUMO
O artigo tem por objetivo revisar os diferentes métodos para o diagnóstico de infecção urogenital por Chlamydia trachomatis. O método utilizado foi à revisão de literatura médica especializada e concluiu-se que na escolha do método diagnóstico deve-se considerar a sensibilidade e especificidade da técnica pretendida, a individualidade do caso e a adequação aos recursos disponíveis. O exame cultural para Chlamydia trachomati constitui-se no teste padrão, por apresentar a melhor especificidade na detecção da infecção. Entretanto, estudos recentes sugerem que as técnicas de amplificação de ácido nucléico têm demonstrado maior sensibilidade e especificidade semelhante ao teste cultural.